David C. Collymore, MD, MBA, believes the field of personalized medicine has seen tremendous developments over the last 5 to 10 years, especially in oncology care.
“The role of genetic testing in both screening and treatment has received a lot of publicity in oncology, particularly in breast cancer,” he said, adding that genetic testing has been integrated into clinical care for the diagnosis of breast cancer to detect specific mutations in tumors. Dr Collymore explained that although it’s not yet the standard of care in screening for cancer risk, individuals have taken it upon themselves to undergo genetic testing to determine their risk of developing cancer.
“Angelina Jolie, who had prophylactic surgery, is a prominent example of this,” Collymore said. He then narrated a personal story of an acquaintance who, being aware of a strong family presence of breast and ovarian cancer, underwent genetic testing herself, followed by prophylactic surgery.
While the field of oncology has seen a lot of advances with respect to screening and treatment based on genetic testing, Dr Collymore believes that other areas such as diabetes and hypertension have also found use for this tool.
In terms of the impact on outcomes, he referenced older studies with tamoxifen in the treatment of breast cancer. “They found that a significant proportion of patients did not respond to treatment [with tamoxifen], which was a major advancement. But there is still a lot of work left to be done to show that it is cost effective,” Dr Collymore said.
Children With AD, Neurodevelopmental Comorbidities at Greater Odds of Learning, Memory Difficulties
March 18th 2024Children with atopic dermatitis (AD) face higher chances of learning and memory difficulties, particularly when they have neurodevelopmental comorbidities, like attention-deficit/hyperactivity disorder.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Disease-, Age-, Genomic-Specific Factors Increase Risk of ET, PV, PrePMF Developing Into Overt MF
March 16th 2024New research highlights the factors that increase the likelihood that essential thrombocytopenia (ET), polycythemia vera (PV), and prefibrotic primary myelofibrosis (PrePMF) will evolve into overt myelofibrosis (MF).
Read More